Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center in July 2026 following clinical trial authorizations from regulators in both Israel and Germany

Expanded the therapeutic profile of SIL204 with new preclinical immuno-oncology data supporting a coordinated immune-sensitization signature across three key immune pathways and four KRAS mutations, reinforcing the rationale for future combination with anti-PD-(L)1 checkpoint inhibitor therapies